BN82451 attenuates l-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease

Neuropharmacology

Volumn 60, Issue 4, 2011, Pages 692-700

  Spinnewyn, Brigitte ^a   Mautino, Gisele ^a   Marin, Jean Gregoire ^a   Rocher, Marie Noëlle ^a   Grandoulier, Anne Sophie ^a   Ferrandis, Eric ^a   Auguet, Michel ^a   Chabrier, Pierre Etienne ^a  

^a IPSEN   (France)

Author keywords

6 OHDA; BN82451; c Fos; Dyskinesia; FosB; l dopa

Indexed keywords

4 [2 (AMINOMETHYL) 1,3 THIAZOL 4 YL] 2,6 DI TERT BUTYLPHENOL; ANTIPARKINSON AGENT; BN 82451; CELL PROTEIN; LEVODOPA; MESSENGER RNA; PROTEIN ARC; PROTEIN C FOS; TRANSCRIPTION FACTOR FOSB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DYSKINESIA; GENE EXPRESSION; GENE OVEREXPRESSION; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

ANIMALS; AREA UNDER CURVE; BEHAVIOR, ANIMAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; GENE EXPRESSION; LEVODOPA; MALE; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLES;

EID: 79251599652     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.11.019     Document Type: Article

References (34)

1. A.A. Abdin, and H.E. Hamouda Mechanism of the neuroprotective role of coenzyme Q10 with or without l-dopa in rotenone-induced parkinsonism Neuropharmacology 55 8 Dec 2008 1340 1346 Epub 2008 Sep 10 55, 1340-1346
2. M. Andersson, A. Hilbertson, and M.A. Cenci Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease Neurobiol. Dis. 6 1999 461 474
3. M. Andersson, C. Konradi, and M.A. Cenci cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum J. Neurosci. 21 2001 9930 9943
4. S.B. Berman, and T.G. Hastings Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease J. Neurochem. 73 1999 1127 1137
5. M.A. Cenci, C.S. Lee, and A. Bjorklund l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur. J. Neurosci. 10 1998 2694 2706
6. M.A. Cenci, A. Tranberg, M. Andersson, and A. Hilbertson Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic l-dopa treatment Neuroscience 94 1999 515 527
7. P.E. Chabrier, and M. Auguet Pharmacological properties of BN82451: a novel multitargeting neuroprotective agent CNS Drug Rev. 13 2007 317 332
8. T.N. Chase, F. Bibbiani, and J.D. Oh Striatal glutamatergic mechanisms and extrapyramidal movement disorders Neurotox Res. 5 2003 139 146
9. T.N. Chase Levodopa therapy: consequences of the nonphysiologic replacement of dopamine Neurology 50 1998 S17 S25
10. S.H. Fox, A.E. Lang, and J.M. Brotchie Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure Mov. Disord. 21 2006 1578 1594
11. J.J. Harnett, V. Roubert, C. Dolo, C. Charnet, B. Spinnewyn, S. Cornet, A. Rolland, J.G. Marin, D. Bigg, and P.E. Chabrier Phenolic thiazoles as novel orally-active neuroprotective agents Bioorg. Med. Chem. Lett. 14 2004 157 160
12. N. Hattoria, M. Wanga, H. Taka, T. Fujimura, A. Yoritaka, S. Kubo, and H. Mochizuki Toxic effects of dopamine metabolism in Parkinson's disease Parkinsonism Relat. Disord. 15 Suppl. 1 2009 S35 S38
13. P.G. Jenner, and M.F. Brin Levodopa neurotoxicity: experimental studies versus clinical relevance Neurology 50 1998 S39 S43
14. P. Jenner Molecular mechanisms of L-DOPA-induced dyskinesia Nat. Rev. Neurosci. 9 2008 665 677
15. K.A. Johnson, P.J. Conn, and C.M. Niswender Glutamate receptors as therapeutic targets for Parkinson's disease CNS Neurol. Disord. Drug Targets 8 2009 475 491
16. P. Klivenyi, R.J. Ferrante, G. Gardian, S. Browne, P.E. Chabrier, and M.F. Beal Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease J. Neurochem. 86 2003 267 272
17. C. Konradi, J.E. Westin, M. Carta, M.E. Eaton, K. Kuter, A. Dekundy, M. Lundblad, and M.A. Cenci Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia Neurobiol. Dis. 17 2004 219 236
18. D. Levesque, and C. Rouillard Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation Trends Neurosci. 30 2007 22 30
19. E. Luginger, G.K. Wenning, S. Bosch, and W. Poewe Beneficial effects of amantadine on l-dopa-induced dyskinesias in Parkinson's disease Mov. Disord. 15 2000 873 878
20. M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M.A. Cenci Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur. J. Neurosci. 15 2002 120 132
21. N. Nishikawa, M. Nagai, T. Moritoyo, H. Yabe, and M. Nomoto Plasma amantadine concentrations in patients with Parkinson's disease Parkinsonism Relat. Disord. 15 2009 351 353
22. N. Pavon, A.B. Martin, A. Mendialdua, and R. Moratalla ERK phosphorylation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice Biol. Psychiatry 59 2006 64 74
23. S. Przedborski, V. Jackson-Lewis, U. Muthane, H. Jiang, M. Ferreira, A.B. Naini, and S. Fahn Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity Ann. Neurol. 34 1993 715 723
24. S. Przedborski, V. Jackson-Lewis, and S. Fahn Antiparkinsonian therapies and brain mitochondrial complex I activity Mov Disord. 10 1995 312 317
25. O. Rascol, and N. Fabre Dyskinesia: l-dopa-induced and tardive dyskinesia Clin. Neuropharmacol. 24 2001 313 323
26. S. Robelet, C. Melon, B. Guillet, P. Salin, and L. Kerkerian-Le Goff Chronic l-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease Eur. J. Neurosci. 20 2004 1255 1266
27. V. Sgambato-Faure, V. Buggia, F. Gilbert, D. Levesque, A.L. Benabid, and F. Berger Coordinated and spatial upregulation of arc in striatonigral neurons correlates with l-dopa-induced behavioral sensitization in dyskinetic rats J. Neuropathol. Exp. Neurol. 64 2005 936 947
28. J.J. Soghomonian l-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus Eur. J. Neurosci. 23 2006 2395 2403
29. Spinnewyn, B., Charnet, C., Cornet, S., Roubert, V., Chabrier, P. E., Auguet, M., An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats. Fundam. Clin. Pharmacol., in press, doi:10.1111/j.1472-8206.2010.00883.x.
30. M. St Hilaire, E. Landry, D. Levesque, and C. Rouillard Denervation and repeated l-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats Neurobiol. Dis. 14 2003 98 109
31. N. Stefanova, M. Lundblad, F. Tison, W. Poewe, M.A. Cenci, and G.K. Wenning Effects of pulsatile l-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy) Neurobiol. Dis. 15 2004 630 639
32. O. Steward, and P.F. Worley Selective targeting of newly synthesized Arc mRNA to active synapses requires NMDA receptor activation Neuron 30 2001 227 240
33. J.E. Westin, M. Andersson, M. Lundblad, and M.A. Cenci Persistent changes in striatal gene expression induced by long-term l-DOPA treatment in a rat model of Parkinson's disease Eur. J. Neurosci. 14 2001 1171 1176
34. C. Winkler, D. Kirik, A. Bjorklund, and M.A. Cenci l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function Neurobiol. Dis. 10 2002 165 186